Sight Sciences Secures Order on Post-Trial Motions

Why It Matters

The ruling reinforces the enforceability of ophthalmic device patents, raising the cost of infringement for major market players and signaling heightened IP risk in the eye‑care sector. It also delivers a sizable financial windfall for Sight Sciences, bolstering its competitive position.

Key Takeaways

• Court upheld $55.4M verdict, denying Alcon's new trial request
• Ongoing royalty set at 10% of Hydrus revenue for patent term
• Total damages could rise as royalties accrue over 2.5 years
• Verdict reinforces patent strength for eye‑care innovators
• Sight Sciences' OMNI system protected against Alcon, Ivantis infringement

Pulse Analysis

The Delaware district court’s decision marks a pivotal moment for patent enforcement in the ophthalmic device market. By preserving a $55.4 million verdict and rejecting Alcon’s post‑trial motions, the court affirmed the jury’s finding that the Hydrus Microstent infringed three Sight Sciences patents (U.S. Nos. 8,287,482; 9,370,443; 11,389,328). This outcome builds on the earlier 2024 jury award of $34 million, which covered lost‑profit and royalty damages, and adds a forward‑looking royalty stream that will track Hydrus sales for the remainder of the patent life.

For industry stakeholders, the judgment sends a clear signal that courts are willing to uphold substantial damages and ongoing royalty obligations when infringement is deemed willful. Competitors developing minimally invasive glaucoma devices must now weigh the heightened risk of costly litigation against the potential market rewards. The 10% royalty, applied to every Hydrus unit sold, creates a recurring financial burden that could influence pricing strategies, product roadmaps, and partnership negotiations across the eye‑care ecosystem.

Financially, the ruling could dramatically increase Sight Sciences’ revenue trajectory. Assuming Hydrus maintains its current market share, the royalty stream over the next two and a half years may add tens of millions of dollars to the $55.4 million base award. This infusion strengthens Sight Sciences’ balance sheet, supports further R&D investment in its OMNI platform, and may attract additional capital interest. Meanwhile, Alcon and Ivantis must account for the immediate cash outlay and the longer‑term royalty liability, potentially prompting settlement discussions in other pending IP disputes.